NCT03671564 - Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

September 11, 2019

Study Completion Date

September 11, 2019

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Milademetan

Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.

Trial Locations (8)

Japanese Red Cross Narita Hospital, Chiba

Kyusyu University Hospital, Fukuoka

Gifu Municipal Hospital, Gifu

Chugoku Central Hospital, Hiroshima

National Hospital Organization Kumamoto Medical Center, Kumamoto

Tenri Hospital, Nara

NTT Medical Center Tokyo, Tokyo

National Hospital Organization Disaster Medical Center, Tokyo